Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel

Michael T. Parsons,Miguel de la Hoya,Marcy E. Richardson,Emma Tudini,Michael Anderson,Windy Berkofsky-Fessler,Sandrine M. Caputo,Raymond C. Chan,Melissa C. Cline,Bing-Jian Feng,Cristina Fortuno,Encarna Gomez-Garcia,Johanna Hadler,Susan Hiraki,Megan Holdren,Claude Houdayer,Kathleen Hruska,Paul James,Rachid Karam,Huei San Leong,Alexandra Martins,Arjen R. Mensenkamp,Alvaro N. Monteiro,Vaishnavi Nathan,Robert O’Connor,Inge Sokilde Pedersen,Tina Pesaran,Paolo Radice,Gunnar Schmidt,Melissa Southey,Sean Tavtigian,Bryony A. Thompson,Amanda E. Toland,Clare Turnbull,Maartje J. Vogel,Jamie Weyandt,George A.R. Wiggins,Lauren Zec,Fergus J. Couch,Logan C. Walker,Maaike P. G. Vreeswijk,David E. Goldgar,Amanda B. Spurdle

DOI: https://doi.org/10.1101/2024.01.22.24301588

2024-01-23

Abstract:The ENIGMA research consortium ( ) develops and applies methods to determine clinical significance of variants in Hereditary Breast and Ovarian Cancer genes. An ENIGMA classification sub-group, originally formed in 2016 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Federal Drug Administration recognized processes for ClinVar contributions. The VCEP reviewed American College of Medical Genetics/Association of Molecular Pathology (ACMG/AMP) classification criteria for relevance to interpreting and variants. Statistical methods were used to calibrate evidence strength for different data types. Pilot specifications were tested on 40 variants, and documentation revised for clarity and ease-of-use. The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 Uncertain Significance or Conflicting, 14 Pathogenic and/or Likely Pathogenic, and 13 Benign and/or Likely Benign. Review resolved classification for 11/13 Uncertain Significance or Conflicting variants, and retained or improved confidence in classification for the remaining variants. Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several gaps in both the research processes and the baseline ACMG/AMP criteria. Calibration of evidence types was key to justify utility and strength of different evidence types for gene-specific application. The gene-specific criteria demonstrated value for improving ACMG/AMP-aligned classification of and variants.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about how to classify variants in BRCA1 and BRCA2 genes more accurately. Specifically, the objectives of the paper are:

1. **Evaluate and adjust the existing ACMG/AMP classification criteria**: The paper mentions that the research team reviewed the variant classification criteria proposed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) to determine the relevance and applicability of these criteria when interpreting variants in BRCA1 and BRCA2 genes. The research team used statistical methods to calibrate the evidence strength of different types of data and tested the application effect of the preliminary specification on 40 variants.

2. **Develop classification criteria specific to BRCA1 and BRCA2**: Based on the above evaluation, the research team developed detailed classification specifications specific to BRCA1 and BRCA2 genes, aiming to improve the accuracy and consistency of variant classification. These specifications not only consider the existing ACMG/AMP criteria, but also combine the previous research results of the ENIGMA research consortium and the experience in clinical practice.

3. **Solve uncertainties and inconsistencies in classification**: By applying the newly developed classification specifications, the research team hopes to solve the uncertainties or conflicts in the classification of certain variants in the ClinVar database, thereby improving the understanding of the clinical significance of these variants.

4. **Promote international standardization**: Ultimately, the development and application of these specifications help to promote the international standardization of the classification of variants in BRCA1 and BRCA2 genes, ensuring consistency and reliability among different laboratories and research institutions.

Through these efforts, the research team hopes to provide a more systematic and scientific framework for evaluating and classifying variants in BRCA1 and BRCA2 genes, so as to better guide clinical decision - making and patient management.